How it works, simply
It mimics GLP-2, a signal that supports the intestinal lining and absorption.
What the evidence tells us
Short-bowel evidence does not establish a benefit for nonspecific gut-health complaints.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
- Intestinal obstruction, fluid overload and growth of abnormal tissue are important concerns.
- Monitoring requirements are specific to this treatment and its population.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Activates GLP-2 receptors to support intestinal mucosal growth and absorption.
Sponsor or developer: Takeda
Studied or labeled topics: Short bowel syndrome
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
- DailyMed: GATTEX prescribing information ↗ · Regulator · Sep 18, 2025
Product labels and further research
These directories help locate records. They are not individual studies supporting every statement.
Readability updated October 10, 2026. Evidence review: October 10, 2026 (linked label: purpose and selected risks). A wording update is not a new clinical review.